Literature DB >> 7828147

Chromosomal disorder and neoplastic diseases in a family with inherited fragile 16. Causality or casualty?

M T Ferro1, J M García-Sagredo, M Resino, E del Potro, A Villegas, J Mediavilla, D Espinós, C San Román.   

Abstract

We describe a family with an inherited fragile chromosome 16 with the concurrence of a constitutional chromosome abnormality, together with neoplastic pathology within the family. The following findings should be pointed out: in relation to the constitutional chromosome pathology, of the proband's 3 children, the eldest daughter was a carrier of the fragile 16, the same as the father, and the second child, a son, had Down syndrome (trisomy 21). Regarding the tumoral pathology of this family, one of the proband's daughters died in childhood from acute lymphoblastic leukemia, whereas the proband developed two different malignant hematologic disorders: a follicular lymphoma and an acute nonlymphocytic leukemia (M5 type). Moreover, two independent acquired chromosome disorders coexisted in the proband; each of these was related to one of the respective hematologic disorders.

Entities:  

Mesh:

Year:  1994        PMID: 7828147     DOI: 10.1016/0165-4608(94)90084-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Anticipation in familial leukemia.

Authors:  M Horwitz; E L Goode; G P Jarvik
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

2.  Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2.

Authors:  M Horwitz; K F Benson; F Q Li; J Wolff; M F Leppert; L Hobson; M Mangelsdorf; S Yu; D Hewett; R I Richards; W H Raskind
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

3.  Chromosomal rearrangement in Down syndrome with acute myeloid leukemia.

Authors:  Chetana Bakshi; Pratibha Amare Kadam; Dhiraj Abhyankar; Chanda Baisane; Shripad Banavali; Suresh Advani
Journal:  Indian J Pediatr       Date:  2003-09       Impact factor: 1.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.